Will All US Biosimilar mAbs Be Interchangeable In The Long Run?
Landmark Adalimumab Approval Sparks Debate For Controversial Designation
As Boehringer Ingelheim’s Cyltezo has become the second-ever interchangeable biosimilar approved by the US FDA – as well as the first monoclonal antibody to garner the designation and offering the first published data from a switching trial to support interchangeability – the debate around the potential impact for interchangeable products in the keenly-watched adalimumab space and beyond continues to grow.
